Tofacitinib reduces KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease. Results of a phase II investigator-initiated study
- DOI
- 10.1016/j.rmed.2026.109150
- Published
- 2026-11
- Container
- Respiratory Medicine
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.rmed.2026.109150,
title = {Tofacitinib reduces KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease. Results of a phase II investigator-initiated study},
author = {Jorge Rojas-Serrano and Espiridión Ramos-Martínez and Mayra Mejía and María Fernanda Castillo-López and Valeria Lira-Boussart and Daphne Rivero-Gallegos and Salvador García-Carmona and Gloria Pérez-Rubio and Ramces Falfán-Valencia},
year = {2026},
journal = {Respiratory Medicine},
doi = {10.1016/j.rmed.2026.109150},
url = {https://doi.org/10.1016/j.rmed.2026.109150}
}RIS
TY - JOUR TI - Tofacitinib reduces KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease. Results of a phase II investigator-initiated study AU - Jorge Rojas-Serrano AU - Espiridión Ramos-Martínez AU - Mayra Mejía AU - María Fernanda Castillo-López AU - Valeria Lira-Boussart AU - Daphne Rivero-Gallegos AU - Salvador García-Carmona AU - Gloria Pérez-Rubio AU - Ramces Falfán-Valencia PY - 2026 JO - Respiratory Medicine DO - 10.1016/j.rmed.2026.109150 UR - https://doi.org/10.1016/j.rmed.2026.109150 ER -
APA
Rojas-Serrano, J., Ramos-Martínez, E., Mejía, M., Castillo-López, M. F., Lira-Boussart, V., Rivero-Gallegos, D., García-Carmona, S., Pérez-Rubio, G., & Falfán-Valencia, R. (2026). Tofacitinib reduces KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease. Results of a phase II investigator-initiated study. Respiratory Medicine. https://doi.org/10.1016/j.rmed.2026.109150
Source records
- crossref · retrieved 2026-09-27T00:42:58.566Z